Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting being held July 15–18, 2026 in Montréal, Québec, Canada.